Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine
NCT ID: NCT02366013
Last Updated: 2016-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
22 participants
INTERVENTIONAL
2015-01-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Volunteers will be screened up to 56 days before vaccination and will be followed for 12 months after vaccination.
Because the vaccine is replication competent, volunteers will be housed in an isolation unit from day -2 through day 9. Household contacts will also be enrolled and tested for possible transmission.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
1 dose of rcAd26.MOS1.HIV-Env 1x10\^8 vp or placebo
rcAd26.MOS1.HIV-Env 1x10^8 vp
1 oral capsule, 1x10\^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
Group 2
1 dose of rcAd26.MOS1.HIV-Env 1x10\^9 vp or placebo
rcAd26.MOS1.HIV-Env 1x10^9 vp
10 oral capsules, 1x10\^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
Group 3
1 dose of rcAd26.MOS1.HIV-Env 1x10\^10 vp or placebo
rcAd26.MOS1.HIV-Env 1x10^10 vp
1 oral capsule, 1x10\^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
Group 4
1 dose of rcAd26.MOS1.HIV-Env 1x10\^11 vp or placebo
rcAd26.MOS1.HIV-Env 1x10^11 vp
10 oral capsules, 1x10\^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rcAd26.MOS1.HIV-Env 1x10^8 vp
1 oral capsule, 1x10\^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
rcAd26.MOS1.HIV-Env 1x10^9 vp
10 oral capsules, 1x10\^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
rcAd26.MOS1.HIV-Env 1x10^10 vp
1 oral capsule, 1x10\^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
rcAd26.MOS1.HIV-Env 1x10^11 vp
10 oral capsules, 1x10\^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability and willingness to provide informed consent.
* Complete an assessment of understanding
* Available for the duration of the trial, including willingness to be kept in an isolation facility
* From Day 10 through 4 months following vaccination must reside alone or with no more than 2 adults (age 18-60) and no minors under age 18
* Good general health as shown by medical history, physical exam, and screening
* Willing to undergo HIV testing and willing to receive risk reduction counseling
* All female volunteers must be willing to undergo urine pregnancy tests
* Sexually active males must be willing to use an effective method of contraception until at least 4 months after vaccination
* Women of child bearing potential commit to use an effective method of contraception when sexually active with males for 4 months after vaccination
* Willing to forgo donations of blood or any other tissues during the study and, for those who test HIV positive due to trial vaccination (vaccine-induced HIV seroreactivity), until the anti-HIV antibody titers become undetectable
* Low risk for HIV infection and willing to maintain low-risk behavior for the trial duration
Exclusion Criteria
* Current or planned participation in another clinical trial of an experimental agent during the study period
* Pregnant or lactating
* Significant acute or chronic disease, including inflammatory bowel disease or other chronic gastrointestinal disease, immunodeficiency syndrome, or condition requiring immunosuppressant medications
* Use of anticancer, antituberculosis or other medications considered significant by the investigator within the previous 6 months
* Receipt of live-attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with Investigational Product (within 14 days for live attenuated influenza vaccine \[LAIV\]); or receipt of other vaccine (e.g., influenza, pneumococcal), allergy treatment with antigen injections or tuberculin skin test within the previous 14 days or planned receipt within 14 days after vaccination with Investigational Product
* Receipt of blood transfusion or blood-derived products within the previous 3 months
* Receipt of HIV vaccine(s) in a prior HIV vaccine trial.
* Previous severe local or systemic reactions to vaccination
* History of splenectomy
* History of seizure in the last 3 years
* Known autoimmune disease
* Asthma other than mild, well-controlled asthma.
* Diabetes mellitus type 1 or type 2
* Thyroidectomy, or thyroid disease requiring medication during the last 12 months
* Angioedema within the last 3 years if episodes are considered serious or have required medication within the last 2 years
* Hypertension
* Body mass index (BMI) ≥ 40
* Bleeding disorder diagnosed by a doctor
* Malignancy (Not excluded: a volunteer with a surgical excision and subsequent observation period that in the investigator's estimation has a reasonable assurance of sustained cure or is unlikely to recur during the study period)
* Psychiatric condition that compromises safety of the volunteer or precludes compliance with the protocol
* All healthcare workers with direct patient contact
* Childcare worker who has direct contact with children
* Individuals employed as food handlers or otherwise engaged in the preparation or delivery of food outside of their place of residence
* Positive urine toxicology test
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Rochester
OTHER
Beth Israel Deaconess Medical Center
OTHER
International AIDS Vaccine Initiative
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Treanor, MD
Role: PRINCIPAL_INVESTIGATOR
University of Rochester
Kathryn Stephenson, MD, MPH
Role: STUDY_CHAIR
Beth Israel Deaconess Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rochester
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stephenson KE, Keefer MC, Bunce CA, Frances D, Abbink P, Maxfield LF, Neubauer GH, Nkolola J, Peter L, Lane C, Park H, Verlinde C, Lombardo A, Yallop C, Havenga M, Fast P, Treanor J, Barouch DH. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS One. 2018 Nov 14;13(11):e0205139. doi: 10.1371/journal.pone.0205139. eCollection 2018.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
rcAd001/IAVI R001
Identifier Type: -
Identifier Source: org_study_id